This is a short study, performed in different countries, to investigate how well one dose of mirabegron mirabegron suspension is taken, how long it stays in the body and how well it is tolerated in children aged 5 to less than 12 years with symptoms of overactive bladder (possibly caused by nerve dysfunction) The primary objective of the trial is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or ov...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder DRAGON To evaluate the dose-response relationship of YM178-OCAS on efficacy in patients with OAB.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2) The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement su...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase IIb, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment with ASP1941 in Combination with Metformin in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone To evaluate the efficacy of a 12-week treatment of 4 doses of ASP1941 in combination with metformin compared to placebo in combination with metformin in subjects with Type 2 Diabetes Mellitus (T2DM) w...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to assess the long-term efficacy and safety of two medicines, solifenacin succinate and mirabegron, taken together or separately, in patients with overactive bladder To evaluate the safety and tolerability of long-term combination treatment of solifenacin (5 mg) with mirabegron (50 mg) compared to solifenacin and mirabegron monotherapy in subjects with overactive ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate (3 mg, 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg, 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms To assess whether the combination of solifenacin succinate (3, 6, 9 mg) and tamsulosin OCAS 0.4 mg provides improved efficacy compared to tamsulosin OCAS 0.4 mg alone in males with LUTS associated wit...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A RANDOMISED, DOUBLE-BLIND STUDY TO COMPARE THE EFFECT ON SYMPATHETIC ACTIVITY AND HEMODYNAMIC PROFILE OF BARNIDIPINE AND AMLODIPINE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION To compare the effect of barnidipine and amlodipine on sympathetic activity by assessment of plasma norepinephrine levels in the forearm after 12 weeks of therapy.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component To assess the efficacy of fixed dose combinations of tamsulosin OCAS 0.4 mg and solifenacin (6 mg and 9 mg) in comparison with tamsulosin OCAS 0.4 mg monotherapy in male subjects with LUTS associated ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder To assess the efficacy of YM178 50 mg qd and YM178 100 mg qd against placebo in the treatment of subjects with symptoms of overactive bladder.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase II, randomized, double-blind, parallel-group, placebo-controlled, 12-week treatment, adaptive proof-of-principle study of twice daily oral dosing of a novel PDE4 inhibitor (ASP9831) in subjects with non-alcoholic steatohepatitis (NASH) Part 1: Objective: To explore exposure to ASP9831 in patients with Non-alcoholic Steatohepatitis (NASH) and to compare the data with healthy volunteer data Part 2: Primary objective: To study the ef...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune